Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial).

Karow A, Reimer J, König HH, Heider D, Bock T, Huber C, Schöttle D, Meister K, Rietschel L, Ohm G, Schulz H, Naber D, Schimmelmann BG, Lambert M.

J Clin Psychiatry. 2012 Mar;73(3):e402-8. doi: 10.4088/JCP.11m06875.

PMID:
22490266
2.

Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial).

Lambert M, Bock T, Schöttle D, Golks D, Meister K, Rietschel L, Bussopulos A, Frieling M, Schödlbauer M, Burlon M, Huber CG, Ohm G, Pakrasi M, Chirazi-Stark MS, Naber D, Schimmelmann BG.

J Clin Psychiatry. 2010 Oct;71(10):1313-23. doi: 10.4088/JCP.09m05113yel. Epub 2010 Mar 23.

PMID:
20361911
3.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
4.

Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.

Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, Ratcliffe M, Hong J, Novick D; SOHO Study Group.

Pharmacoeconomics. 2008;26(4):341-58.

PMID:
18370568
5.

Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia.

Järbrink K, Kreif N, Benedict A, Locklear J.

Curr Med Res Opin. 2009 Mar;25(3):709-16. doi: 10.1185/03007990902738810 .

PMID:
19196221
6.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

7.

Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.

Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT.

Curr Med Res Opin. 2004 Dec;20(12):1883-93.

PMID:
15701206
8.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

9.

Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.

Zeidler J, Mahlich J, Greiner W, Heres S.

Appl Health Econ Health Policy. 2013 Oct;11(5):509-21. doi: 10.1007/s40258-013-0050-0. Erratum in: Appl Health Econ Health Policy. 2013 Dec;11(6):689.

PMID:
23975630
10.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
11.

Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.

Ascher-Svanum H, Furiak NM, Lawson AH, Klein TM, Smolen LJ, Conley RR, Culler SD.

J Med Econ. 2012;15(3):531-47. doi: 10.3111/13696998.2012.662923. Epub 2012 Feb 21.

PMID:
22304338
12.

Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release.

Rajagopalan K, O'Day K, Meyer K, Pikalov A, Loebel A.

J Med Econ. 2013 Aug;16(8):987-96. doi: 10.3111/13696998.2013.809353. Epub 2013 Jun 21.

PMID:
23742620
13.

Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.

Park T, Kuntz KM.

Value Health. 2014 Jun;17(4):310-9. doi: 10.1016/j.jval.2014.02.008. Epub 2014 May 10.

14.

Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis.

Fajutrao L, Paulsson B, Liu S, Locklear J.

Clin Ther. 2009 Jun;31 Pt 1:1456-68. doi: 10.1016/j.clinthera.2009.06.009.

PMID:
19698903
15.

Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.

Law WL, Hui HY, Young WM, You JH.

Int J Clin Pharmacol Ther. 2007 May;45(5):264-70.

PMID:
17542348
16.

Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.

Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.

J Ment Health Policy Econ. 2008 Jun;11(2):89-97.

PMID:
18509216
17.
18.

Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial).

Michaels JA, Campbell WB, Brazier JE, Macintyre JB, Palfreyman SJ, Ratcliffe J, Rigby K.

Health Technol Assess. 2006 Apr;10(13):1-196, iii-iv. Review.

19.

The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia.

Lynch J, Morrison J, Graves N, Meddis D, Drummond MF, Hellewell JS.

Eur Psychiatry. 2001 Aug;16(5):307-12.

PMID:
11514134
20.
Items per page

Supplemental Content

Write to the Help Desk